tbuckley/cabot-search huggingface dataset:
Functional Kidney Bioengineering with Pluripotent Stem‐Cell‐Derived Renal Progenitor Cells and Decellularized Kidney Scaffolds
Authors: Chan Du, Karthikeyan Narayanan, Meng Fatt Leong, Mohammed Shahrudin Ibrahim, Ying Ping Chua, Vanessa Mei Hui Khoo, Andrew C. A. Wan
Journal: Advanced Healthcare Materials (2016)

Recent advances in developmental biology and stem cell technology have led to the engineering of functional organs in a dish. However, the limited size of these organoids and absence of a large circulatory system poses limits to its clinical translation. To overcome these issues, decellularized whole kidney scaffolds with native microstructure and extracellular matrix (ECM) are employed for kidney bioengineering, using human‐induced pluripotent‐stem‐cell‐derived renal progenitor cells and endothelial cells. To demonstrate ECM‐guided cellular assembly, the present work is focused on generating the functional unit of the kidney, the glomerulus. In the repopulated organ, the presence of endothelial cells broadly upregulates the expression level of genes related to renal development. When the cellularized native scaffolds are implanted in SCID mice, glomeruli assembly can be achieved by co‐culture of the renal progenitors and endothelial cells. These individual glomerular units are shown to be functional in the context of the whole organ using a simulated bio‐reactor set‐up with urea and creatinine excretion and albumin reabsorption. Our results indicate that the repopulation of decellularized native kidney using clinically relevant, expandable patient‐specific renal progenitors and endothelial cells may be a viable approach for the generation of a functional whole kidney.
Increased 99mTc-MDP Activity in a Partially Calcified Malignant Mediastinal Teratoma
Authors: Wei Li, Linqi Zhang, Rusen Zhang
Journal: Clinical Nuclear Medicine (2015)

A 41-year-old woman presented with cough and shortness of breath for 3 weeks. Chest x-ray and CT showed a large, partially calcified soft tissue mass adjacent to the right side of the heart. Whole-body bone was acquired to evaluate possible metastases, which showed abnormal accumulation of 99mTc-MDP in the right chest. Further SPECT/CT imaging that demonstrated intense 99mTc-MDP activity was mainly in the calcification portion of mass. Histopathological examination from biopsy specimen of the lesion was consistent with malignant teratoma.
MB-49INTENSIVE TREATMENT OF HIGH-RISK MEDULLOBLASTOMA (HR-MB): HOW TO LEARN FROM TOXICITIES IN AN EUROPEAN SETTING OF RADIOTHERAPISTS AND PHYSICISTS OF THE SIOP BRAIN TUMOR WORKING GROUP
Authors: Lorenza Gandola, Gail Horan, Silvia Meroni, Jordi Giralt, Helen Mayles, Nicky Thorp, Simon Bailey, Barry Pizer, Monica Ramos, Laetitia Padovani, Nicolas Andre, Claude Malet, François Doz, Geert O. Janssens, Foppe Oldenburger, James Hayden, Rolf D. Kortmann, Stefan Rutkowski, Maura Massimino, Tommaso Giandini, Emanuele Pignoli
Journal: Neuro-Oncology (2016)
Abstract 4099: Genetic and Clinical Predictors of Response to Rate Control Therapy in Patients with Atrial Fibrillation
Authors: Joseph C Vaglio, Shane B Rowan, Gayle Kucera, Tanya D Stubblefield, Shannon Carter, Dan M Roden, Dawood Darbar
Journal: Circulation (2008)

Background: Randomized studies have now shown that ventricular rate control is an acceptable strategy in patients with atrial fibrillation (AF). Beta-blockers are the first line pharmacologic agent used for ventricular rate control. Recently, a non-synonymous polymorphism (G389R) in the beta-1-adrenergic receptor has been found to modulate the outcome of beta-blockade in heart failure patients. Accordingly, in this study we evaluated the impact of clinical factors and of two common polymorphisms in the β1-adrenergic receptor (G389R and S49G) on response to ventricular rate control therapy in patients with AF. Methods and Results: We studied 279 patients (200 men, 79 women, ages 55 ± 13 years) prospectively enrolled in the Vanderbilt AF Registry, and managed with rate control. Ventricular rate control was prospectively defined as adequate based on the AFFIRM criteria: Average heart rate (HR) at rest ≤80 bpm and Maximum HR during 6-min walk test ≤110 bpm or average HR during 24-hr Holter ≤100 bpm. Non-response was defined when the ventricular rate was inadequately controlled necessitating a change in therapy. In 151 (54.1%) patients, ventricular rate control was classified as adequate. Although the frequencies of the two â1-adrenergic polymorphisms were in Hardy-Weinberg equilibrium (G389R: 0.25 [cases] vs 0.26 [controls]; S49R: 0.14 [cases] vs. 0.24 [controls], both P&gt;0.05), they were not significantly associated with ventricular rate control (P&gt;0.05 for both). However, a history of hypertension, hyperlipidemia, valvular heart disease and cardiomyopathy were significantly associated with inadequate ventricular rate control. Conversely, prior stroke was more common in patients with adequate ventricular rate control (odds ratio [OR] = 0.29; P&lt;0.01). Conclusions: We have identified clinical predictors of response to ventricular rate therapy in patients with AF. However, common β1-adrenergic receptor polymorphisms did not modulate response to rate control therapy. Future studies are needed to confirm these findings in other cohorts and to elucidate potential clinical decision-making tools to predict response to rate control therapy in AF patients.
TP53 mutation is infrequent in aneuploid choroid plexus tumours
Authors: Tracy Warr, Michael O. Idowu, Blanca Suarez-Merino, Samantha Ward, William Harkness, Richard Hayward, Dominic Thompson, John L. Darling, David G. Thomas
Journal: Neuro-Oncology (2003)

Abstracts from Neuro-Oncology are provided here courtesy of Society for Neuro-Oncology and Duke University Press.
Evaluating antianxiety agents in humans: experimental paradigms
Authors: E H Uhlenhuth
Journal: American Journal of Psychiatry (1977)

Conventional clinical trials using parallel groups are relatively insensitive to the effects of psychotropic drugs, especially antianxiety agents. Experimental paradigms based on the single organism research strategy offer an alternative. A free operant avoidance procedure clearly distinguished representative psychotropic compounds, including diazepam and pentobarbital, in normal subjects, and a multiple crossover procedure clearly detected antianxiety effects of diazepam in 11 psychoneurotic patients and antipsychotic effects of chlordiazepoxide in individual schizophrenic patients. Such procedures may serve to evaluate the effectiveness of therapeutic interventions in clinical practice as well as in research.
A View From Outside: 1963–77—&lt;italic&gt;Historical Note&lt;/italic&gt;&lt;xref ref-type="fn" rid="fn2"&gt;2&lt;/xref&gt;&lt;xref ref-type="fn" rid="fn3"&gt;3&lt;/xref&gt;
Authors: M B Shimkin
Journal: JNCI Journal of the National Cancer Institute (1979)
Response to: ‘Additional proposals to reduce comorbidity in patients with chronic inflammatory rheumatic diseases’. Screening for comorbidities: what is the remit of rheumatologists?
Authors: Athan Baillet, Laure Gossec, Maxime Dougados
Journal: Annals of the Rheumatic Diseases (2016)

We thank Castaneda et al 1 for their interest in our paper2 and are pleased to have the opportunity to respond to their comments in order to clarify what part of the management of comorbidities we believe to be within the remit of rheumatologists, that is, what is likely to be done by the rheumatologist and what rheumatologists are able to do in the daily practice.

The European League Against Rheumatism (EULAR) task force anticipated that the screening of a wide scope of comorbidities would make the final process too complex or too extensive to be implemented. The EULAR task force acknowledged that fibromyalgia impacts on the assessment of the disease activity and response to treatment of chronic …
Stop-Gap Measure Developed For Faltering Cardiac Pacemaker
Authors: W T SATTERFIELD
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Eye of the Beholder
Authors: Lindsey MacFarlane, Nora Osman, Anand Vaidya, Anthony A. Amato, Susan Ritter
Journal: New England Journal of Medicine (2016)

A 47-year-old man presented to an urgent care ambulatory clinic with a 3-day history of swelling around his left eye and a sensation of tightness in his throat. It had become difficult for him to swallow solids, and he felt as if food was sticking in his throat. The patient had no shortness of breath or wheezing, but 1 day before presentation he felt his voice was becoming hoarse. He . . .
Editorial
Authors: A. Katsambas
Journal: British Journal of Dermatology (2008)

Treatment of psoriasis, a chronic inflammatory systemic disease associated with a high disease burden and stigmatization of patients, has been revolutionized by targeted biological therapies, which were first introduced in 2002. Nowadays, several biological agents with different modes of action are licensed for the treatment of moderate-to-severe psoriasis and new biologicals will add further choice to the existing treatment palette. The aim of this supplement is it to review currently available data for T-cell-directed and TNF-blocking agents (article by Dr D. Thaçi), the psoriasis-associated comorbidities (article by Dr W. Gulliver) and the atherosclerotic risks linked to psoriasis (article by Dr F. Späh). The article by Dr Thaçi discusses the safety and efficacy data for conventional systemic therapies in the light of biological therapies. There was early recognition of the association between psoriasis and psoriatic arthritis, inflammatory bowel disease and psychological disorders. Dr Gulliver extends this association to metabolic dysfunction and discusses the possible underlying link to systemic inflammation and dysregulation of the immune system. His observation that the lifespan of psoriasis patients is, on average, reduced by 10 years is particularly worrisome. Dr Späh discusses the cardiovascular complications for the psoriasis patient in more detail. The authors suggest that future 'integrated' approaches should tackle the underlying inflammatory mechanism of psoriasis and associated comorbidities. What are the implications for a dermatologist? Psoriasis is a complex immune disorder that affects more than just the skin. Efficient, long-term management will require effective control of the systemic inflammatory process. Consultation for concomitant cardiometabolic disease might be a necessary step for successful long-term management of this chronic inflammatory systemic disease. The editor has declared no conflicts of interest.
Transplantation of bone marrow cells from transgenic mice expressing the human MDR1 gene results in long-term protection against the myelosuppressive effect of chemotherapy in mice
Authors: GH Mickisch, I Aksentijevich, PV Schoenlein, LJ Goldstein, H Galski, C Stahle, DH Sachs, I Pastan, MM Gottesman
Journal: Blood (1992)
Maintenance of an insanity defense under Montana's "abolition" of the insanity defense
Authors: H J Steadman, L A Callahan, P C Robbins, J P Morrissey
Journal: American Journal of Psychiatry (1989)

In 1979, Montana's insanity defense was replaced with the more restrictive mens rea defense, a change that has been described as an example of "abolition" of the insanity defense. The authors identified cases in which mental health was an issue in seven Montana counties for 3 years before and 3 years after the 1979 reform. They found that acquittals based on the insanity plea markedly declined, but that dismissals based on incompetence to stand trial increased substantially following the reform. They conclude that dismissal based on incompetence to stand trial became a substitute for acquittal based on the insanity plea under mens rea.
Evaluation of cytokine responses against novel Mtb antigens as diagnostic markers for TB disease
Authors: Dolapo O. Awoniyi, Andrea Teuchert, Jayne S. Sutherland, Harriet Mayanja-Kizza, Rawleigh Howe, Adane Mihret, Andre G. Loxton, Jacob Sheehama, Desta Kassa, Amelia C. Crampin, Hazel M. Dockrell, Martin Kidd, Ida Rosenkrands, Annemieke Geluk, Tom H.M. Ottenhoff, P.L.A.M. Corstjens, Novel N. Chegou, Gerhard Walzl, Gerhard Walzl, Novel N. Chegou, Magdalena Kriel, Gian van der Spuy, Andre G. Loxton, Kim Stanley, Stephanus Malherbe, Shirley Mcanda, Belinda Kriel, Khutso G. Phalane, Paulin Essone, Jayne S. Sutherland, Olumuyiwa Owolabi, Abdou Sillah, Joseph Mendy, Awa Gindeh, Simon Donkor, Toyin Togun, Martin Ota, Amelia C. Crampin, Felanji Simukonda, Alemayehu Amberbir, Femia Chilongo, Rein Houben, Desta Kassa, Atsbeha Gebrezgeabher, Getnet Mesfin, Yohannes Belay, Gebremedhin Gebremichael, Yodit Alemayehu, Marieta van der Vyver, Faustina N. Amutenya, Josefina N. Nelongo, Lidia Monye, Jacob A. Sheehama, Scholastica Iipinge, Harriet Mayanja-Kizza, Ann Ritah Namuganga, Grace Muzanye, Mary Nsereko, Pierre Peters, Rawleigh Howe, Adane Mihret, Yonas Bekele, Bamlak Tessema, Lawrence Yamuah, Tom H.M. Ottenhoff, Annemieke Geluk, Kees Franken, Paul L.A.M. Corstjens, Elisa M. Tjon Kon Fat, Claudia J. de Dood, Jolien J. van der Ploeg-van Schip, Ida Rosenkrands, Claus Aagaard, Stefan H.E. Kaufmann, Maria M. Esterhuyse, Jacqueline M. Cliff, Hazel M. Dockrell
Journal: Journal of Infection (2016)
LG-46INFERIOR OUTCOME AND POOR RESPONSE TO CONVENTIONAL THERAPIES IN PEDIATRIC LOW-GRADE GLIOMAS HARBORING THE BRAF V600E MUTATION
Authors: Alvaro Lassaletta, Matthew Mistry, Anthony Arnaldo, Scott Ryall, Ana Guerreiro-Stucklin, Rahul Krishnatry, Cino Ling, Marion Honnorat, Nataliya Zhukova, Michal Zapotocky, Tara McKeown, Vijay Ramaswamy, Ute Bartels, Annie Huang, Nada Jabado, Ofelia Cruz, Carmen de Torres, Ho Cherry, Roger Packer, Ruth Tatevossian, David Ellison, Julie Harreld, Jim Dalton, Jean Mulcahy-Levy, Nicholas Foreman, Matthias Karajannis, Sabine Mueller, Theodore Nicolaides, David Eisenstat, Anne-Sophie Carret, Mark Kieran, Keith Ligon, Anne Jouvet, Romain Perbert, Alex Vasiljevic, Didier Frappaz, Marie Odile Joly, Lola Chambeless, Reid Thompson, Amulya Nageswara Rao, Aden Chan, Hk NG, Maria Luisa Garre, Paolo Nozza, Maura Massimino, Sarah Leary, Courtney Crane, Eric Bouffet, Cynthia Hawkins, Uri Tabori
Journal: Neuro-Oncology (2016)
Exploring the potential of porous silicas as a carrier system for dissolution rate enhancement of artemether
Authors: Jaywant N. Pawar, Harita R. Desai, Kailas K. Moravkar, Deepak K. Khanna, Purnima D. Amin
Journal: Asian Journal of Pharmaceutical Sciences (2016)

Malaria is a parasitic and vector determined blood-conceived infectious disease transmitted through infected mosquitoes. Anti-malarial drug resistance is a major health problem, which hinders the control of malaria. A Results of a survey of drug-resistant malaria demonstrated safe proclivity to nearby all anti-malarial regimes accessible except from artemisinin and its derivatives. Artemether is a BCS class IV drug effective against acute and severe falciparum malaria; hence there is a strong need to improve its solubility. Silica is one of the most widely studied excipients. Silica can be used in solubility enhancement by preparing its solid solution/dispersion with the drug. The objective of this research was to improve dissolution rate of Artemether using non-precipitated porous silica (Aeroperl 300 Pharma) and precipitated silica like EXP. 9555, EXP. 9560, and EXP. 9565. Specific surface area calculated from BET method of porous silicas viz. APL 300 (A), Exp. 9555 (B), Exp. 9560 (C), Exp. 9565 (D) was found to be 294.13 m2/g (A), 256.02 m2/g (B), 213.62 m2/g (C) and 207.22 m2/g (D) respectively.The drug release from the developed formulation was found to be significantly higher as compared to neat ARM. This improved solubility and release kinetics of ARM may be attributed to high surface area, improved wettability and decreased crystallinity. Solid-state characterization of the developed optimized formulation F3 was carried out with respect to FTIR chemical imaging, XRD, SEM, and DSC. All the porous silicas which we have explored in the present context showed a significant capability as a carrier for solubility enhancement of ARM.
Proteomic Comparison of Two-Dimensional Gel Electrophoresis Profiles from Human Lung Squamous Carcinoma and Normal Bronchial Epithelial Tissues
Authors: Cui Li, Xianquan Zhan, Maoyu Li, Xiaoying Wu, Feng Li, Jianling Li, Zhiqiang Xiao, Zhuchu Chen, Xueping Feng, Ping Chen, Jingyun Xie, Songping Liang
Journal: Genomics Proteomics & Bioinformatics (2003)

Abstract Differential proteome profiles of human lung squamous carcinoma tissue compared to paired tumor-adjacent normal bronchial epithelial tissue were established and analyzed by means of immobilized pH gradient-based two-dimensional polyacrylamide gel electrophoresis (2-D PAGE) and matrix-assisted laser desorption/ionization time of flight mass spectrometry (MALDI-TOF-MS). The results showed that well-resolved, reproducible 2-DE patterns of human lung squamous carcinoma and adjacent normal bronchial epithelial tissues were obtained under the condition of 0.75-mg protein-load. The average deviation of spot position was 0.733±0.101 mm in IEF direction, and 0.925±0.207 mm in SDS-PAGE direction. For tumor tissue, a total of 1241±88 spots were detected, 987±65 spots were matched with an average matching rate of 79.5%. For control, a total of 1190±72 spots were detected, and 875±48 spots were matched with an average matching rate of 73.5%. A total of 864±34 spots were matched between tumors and controls. Forty-three differential proteins were characterized: some proteins were related to oncogenes, and others involved in the regulation of cell cycle and signal transduction. It is suggested that the differential proteomic approach is valuable for mass identification of differentially expressed proteins involved in lung carcinogenesis. These data will be used to establish human lung cancer proteome database to further study human lung squamous carcinoma.
RO-10PROSPECTIVE SLOPES OVER EIGHT YEARS IN COGNITIVE MARKERS OF PHOTON RADIOTHERAPY FOR PEDIATRIC BRAIN TUMORS
Authors: Carol L. Armstrong, Julie Petersen, Michael J. Fisher, Robert A. Lustig, Jane E. Minturn, Jean B. Belasco, Sarah Amedoro, Cathy Bolton, Peter C. Phillips, Christine E. Hill-Kayser
Journal: Neuro-Oncology (2016)

RO-10. PROSPECTIVE SLOPES OVER EIGHT YEARS IN COGNITIVE MARKERS OF PHOTON RADIOTHERAPY FOR PEDIATRIC BRAIN TUMORS Carol L. Armstrong1,2, Julie Petersen1,3, Michael J. Fisher1,2, Robert A. Lustig1,2, Jane E. Minturn1,2, Jean B. Belasco1,2, Sarah Amedoro1, Cathy Bolton3, Peter C. Phillips1,2, and Christine E. Hill-Kayser1,2; The Children’s Hospital of Philadelphia, Philadelphia, PA, USA; The Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA; Drexel University, Philadelphia, PA, USA PURPOSE: This prospective longitudinal study examined late-delayed effects (pre-treatment to 8y) of IMRT/conformal photon radiotherapy (RT) on cognition in children with brain tumors. We previously demonstrated that memory systems are affected differentially by RT, and investigated the pattern over eight years of these RT-specific cognitive markers. At the latedelayed phase, clinical information suggests a generalized decline in cognition, but no prospective studies report the late phase cognitive toxicity (.5 yr post treatment). METHODS: Participants were 28 patients with mixed primary brain tumors (18 males; age range: 4-17, M 1⁄4 9.04, SD 1⁄4 3.32; 61% had grosstotal resection)whocompletedbaseline andat leastone follow-upassessment frombaseline-8years (115 visits). Verbal-semantic memory wasassessed using a supraspan test of word memory (Rey Auditory Verbal Learning (RAVL, 4-forms)) for encoding, retrieval after interference, and retrieval after a delay. Complex Figure (CF, 2-forms) measured visuoperceptual memory immediately and after delay. Picture Recognition (PR) measured visual-semantic memory (accuracy, speed to recognize). Analyses used age-referenced Z scores in a mixed effects model; whole brain versus focal RT was a covariate. RESULTS: Verbal retrieval indices, but not encoding, were sensitive to the late-effects with progressive decline, and greater detriment in hippocampus-sensitive delayed retrieval. CF recall demonstrated continuous improvement to eight years. Bi-hemispherically processed PR demonstrated no decline over eight years. Dose burden significantly predicted retrieval but not encoding or recognition. CONCLUSIONS: Results evidence significant change over time, with differential changes in cognition, and no general decline. The sensitivity of retrieval infers multi-substrate injury not limited to hippocampus. Neuro-Oncology 18:iii159–iii164, 2016. doi:10.1093/neuonc/now082.10 #The Author(s) 2016. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Cytomegalic Inclusion Disease
Authors: C HOOFT, M J DELBERKE, M DE GROODT
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal